Business
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a Phase 2 trial\nData highlight potential for synergy to enhance anti-cancer effects and overcome resistance in non-small cell lung cancer\nLOS ANGELES, April 9, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, taking place April 5-10, 2024.\nPoster presentation details and abstract highlights include:\nTitle: \"Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines\"Presenting Author: Shihe Hou, PhDSession Title: Reversal of Drug ResistancePoster Number: Poster Section 25; Poster 6Date/Time: Wednesday, April 10, 2024, 9:00 AM – 12:30 PM\nFulvestrant, the selective estrogen receptor degrader and PI3K inhibitors, such as alpelisib, have demonstrated efficacy in patients with HR+ PI3K-mutated breast cancer; however, resistance still occursnab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cellsThe addition of nab-sirolimus to endocrine therapy or PI3K-AKT-mTOR pathway inhibitors may mutually overcome mechanisms of resistance induced by single-agent treatmentsThese data further support the combination of nab-sirolimus with endocrine therapy for hormone-driven cancers, as is currently being investigated in patients with advanced or recurrent endometrioid endometrial cancer in a Phase 2 study (NCT05997017)Title: \"Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors\"Presenting Author: Shihe Hou, PhDSession Title: Targeting Kinase and ERK Pathwa...